Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR vs Octreotide LAR in refractory carcinoid tumors
NCT00690430Phase 3
Key facts
- Status
- Completed
- Start
- Apr 2008
- Primary completion
- Apr 2012
- Countries
- 16
- Sponsor
- Novartis
- Drugs
- pasireotide LAR
- Conditions
- Carcinoid Tumor (CT)
01
Overview
Phase 3, randomised, double-blind trial of pasireotide LAR in Carcinoid Tumor (CT), sponsored by Novartis. Primary endpoint: Percentage of Patients Who Achieved Clinical Symptom Improvement at Month 6. Started Apr 2008; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults with metastatic carcinoid tumors and symptoms (diarrhea/flushing) refractory to somatostatin analogues, with controlled blood glucose and no symptomatic cholelithiasis.
04
Endpoints
Primary
Percentage of Patients Who Achieved Clinical Symptom Improvement
Beyond the preview
Go deeper on NCT00690430.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00690430.